FDA NDC

Baxdela

This name is from the loaded FDA file.

Source: FDA NDC Directory, live from openFDA. Publisher page

NDC
70842-102
Proprietary name
Baxdela
Nonproprietary name
delafloxacin meglumine
Labeler
Melinta Therapeutics, LLC
Dosage form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Strength
300 mg/10.5mL

Run it in Rivvi

Which 2027 plans near you dropped or restricted delafloxacin meglumine?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, from the CMS Part D files.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Try it on your own data today.

Free to start. Most teams are using it the same day.